[Experience in switching monoclonal antibodies in a patient with severe refractory atopic dermatitis: from Dupilumab to Abrocitinib. Case report].
Аннотация
BACKGROUND
Atopic dermatitis is a chronic inflammatory disease that affects the skin and is characterized by intense pruritus and eczema. It requires systemic therapies and the use of novel treatments, such as Dupilumab and Janus kinase inhibitors. The approval of these drugs has revolutionized treatment during the last years.
CASE REPORT: We present a case of a patient with severe atopic dermatitis, refractory to immunosuppressive treatment and his evolution after starting treatment with monoclonal antibodies.
CONCLUSIONS
Monoclonal antibodies are advanced and novel therapies that have demonstrated efficacy in patients with moderate to severe atopic dermatitis. In this article we present a case of a patient with switch of treatment, who had improvement in his evolution and quality of life, demonstrating an adequate response according to the dermatitis scoring index (SCORAD) after treatment with Abrocitinib.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.